____________
Resources:
1 Ho, Dr. Tony W., MD; Ferrari, Prof. Michael D, MD; Dodick, Prof. David W., MD; Galet, Vince, PhD; Kost, James, PhD; Fan, Xiaoyn, PhD; Leibensperger, Heather, BS; Froman, Samar, BS, Assaid, Christopher, PhD; Oines, Christopher, PhD; Koppen, Hille, MD; Winner, Paul K., DO. "Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial." The Lancet, Early Online Publication. November 25, 2008.
2 "New Migraine Drug Shows Promise." HealthDay News. November 24, 2008.
3 News Release: "Merck & Co., Inc.'s Investigational Migraine Treatment Telcagepant Relieved Migraine Pain and Symptoms in Latest Phase III Study." Merck. Chicago. September 6, 2008.
4 "Merck's Investigational Migraine Treatment Telcagepant Improved Pain And Migraine-Associated Symptoms In Phase III Study." Medical News Today. June 30, 2008.
5 News Release: “Merck’s Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study.” Merck. Chicago. June 7, 2007.
6 Interview: Teri Robert with Tony Ho., M.D., senior director of Clinical Neurosciences, Merck Research Laboratories. June 7, 2007.
© Teri Robert, 2008.
Last updated December 1, 2008.
